The aim of iron chelation therapy in thalassaemia

This publication has 9 references indexed in Scilit:

• Prevention of Iron Overload and Long Term Maintenance of Normal Iron Stores in Thalassaemia Major Patients using Deferiprone or Deferiprone Deferoxamine Combination
  Drug Research, 2017
• Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion‐dependent thalassaemia
  European Journal of Haematology, 2017
• Transition of Thalassaemia and Friedreich ataxia from fatal to chronic diseases
  World Journal of Methodology, 2014
• The importance of spleen, spleen iron, and splenectomy for determining total body iron load, ferrikinetics, and iron toxicity in thalassemia major patients
  Toxicology Mechanisms and Methods, 2012
• Liver iron and serum ferritin levels are misleading for estimating cardiac, pancreatic, splenic and total body iron load in thalassemia patients: factors influencing the heterogenic distribution of excess storage iron in organs as identified by MRI T2*
  Toxicology Mechanisms and Methods, 2012
• Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy
  European Journal of Haematology, 2010
• Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major
  British Journal of Haematology, 2010
• Assessment of iron distribution between liver, spleen, pancreas, bone marrow, and myocardium by means of R2 relaxometry with MRI in patients with β‐thalassemia major
  Journal of Magnetic Resonance Imaging, 2009
• SURVIVAL AND CAUSES OF DEATH IN THALASSAEMIA MAJOR
  The Lancet, 1989